生命科学资讯

Exciva raises $59M Series B to fund Phase 2 test of Alzheimer’s agitation drug

Illumina: What Is Next In This Sequence? (NASDAQ:ILMN) - Seeking Alpha

The Bull Case For Illumina (ILMN) Could Change Following Its Billion Cell Atlas Pharma Alliance - Yahoo Finance Singapore

Nucleotide Market Is Going to Boom | Agilent Technologies • Bio-Rad Laboratories • QIAGEN - openPR.com

Is Waters Corporation the Quiet Wall Street Cheat Code Everyone’s Sleeping On? - AD HOC NEWS

Profit Recap: Is Agilent Technologies Inc showing insider buying - Quarterly Earnings Summary & AI Driven Stock Price Forecasts - baoquankhu1.vn

Thermo Fisher Scientific Inc. (TMO): A Bull Case Theory - Insider Monkey

FDA Grants RMAT Designation to iRegene’s NouvNeu001, Cementing its Lead as the World’s First iPSC Therapy with Both FTD and RMAT Recognitions

AstraZeneca pens $630M pact to secure remaining rights to armored CAR-T from AbelZeta

Thermo Fisher Scientific Inc.: BCC Research Releases Comprehensive 360° Company Analysis - Yahoo Finance

The Zacks Analyst Blog Highlights Visa, Advanced Micro Devices and Thermo Fisher Scientific - Zacks Investment Research

Zincure synthesizes new MMP-9 inhibitors

Chong Kun Dang Pharmaceutical discovers new GLP-1R agonists

Negio Therapeutics patents α2-adrenoceptor agonists

Nanjing Chia Tai Tianqing Pharmaceutical identifies new somatostatin SST2 receptor agonists

Shenzhen Newrosetta Biosciences discloses new muscarinic M2 receptor antagonists

Cathie Wood's weekly update: buys Broadcom, AMD; sells Tesla, Illumina - MSN

Immunology biotech Agomab, eye-focused SpyGlass are latest biotechs to share IPO ambitions

Agilent Technologies, Inc. (NYSE:A) S&P 500 Today Global Lab Support - Kalkine Media

Gas Chromatography Systems Market to Reach US$ US$7,203.59 - openPR.com